Reactive oxygen species and ovarian diseases: Antioxidant strategies.

Antioxidant drugs Hormones Mesenchymal stem cells Ovarian diseases Oxidative stress Reactive oxygen species

Journal

Redox biology
ISSN: 2213-2317
Titre abrégé: Redox Biol
Pays: Netherlands
ID NLM: 101605639

Informations de publication

Date de publication:
06 2023
Historique:
received: 15 02 2023
revised: 02 03 2023
accepted: 05 03 2023
medline: 12 5 2023
pubmed: 15 3 2023
entrez: 14 3 2023
Statut: ppublish

Résumé

Reactive oxygen species (ROS) are mainly produced in mitochondria and are involved in various physiological activities of the ovary through signaling and are critical for regulating the ovarian cycle. Notably, the imbalance between ROS generation and the antioxidant defense system contributes to the development of ovarian diseases. These contradictory effects have critical implications for potential antioxidant strategies that aim to scavenge excessive ROS. However, much remains to be learned about how ROS causes various ovarian diseases to the application of antioxidant therapy for ovarian diseases. Here, we review the mechanisms of ROS generation and maintenance of homeostasis in the ovary and its associated physiological effects. Additionally, we have highlighted the pathological mechanisms of ROS in ovarian diseases and potential antioxidant strategies for treatment.

Identifiants

pubmed: 36917900
pii: S2213-2317(23)00060-5
doi: 10.1016/j.redox.2023.102659
pmc: PMC10023995
pii:
doi:

Substances chimiques

Reactive Oxygen Species 0
Antioxidants 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102659

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Junzhi Liang (J)

Center of Reproductive Medicine, Shengjing Hospital of China Medical University, Shenyang, 110004, China.

Yingzhuo Gao (Y)

Center of Reproductive Medicine, Shengjing Hospital of China Medical University, Shenyang, 110004, China.

Ziyi Feng (Z)

Department of Plastic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.

Bowen Zhang (B)

Center of Reproductive Medicine, Shengjing Hospital of China Medical University, Shenyang, 110004, China.

Zhijing Na (Z)

Center of Reproductive Medicine, Shengjing Hospital of China Medical University, Shenyang, 110004, China; Key Laboratory of Reproductive and Genetic Medicine (China Medical University), National Health Commission, Shenyang, 110004, China. Electronic address: sharon_na@foxmail.com.

Da Li (D)

Center of Reproductive Medicine, Shengjing Hospital of China Medical University, Shenyang, 110004, China; Key Laboratory of Reproductive and Genetic Medicine (China Medical University), National Health Commission, Shenyang, 110004, China; Key Laboratory of Reproductive Dysfunction Diseases and Fertility Remodeling of Liaoning Province, Shenyang, 110004, China. Electronic address: leeda@ymail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH